SCHEMBL8601010

SCHEMBL8601010

c1ccc(COc2ccc(OC3CCCCO3)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.46
CYP1A2 P05177 1/20 0.46
PTGS1 P23219 1/20 0.46
SLC6A2 P23975 1/20 0.46
CYP2C19 P33261 1/20 0.46
PTGS2 P35354 1/20 0.46
SLC6A3 Q01959 1/20 0.46
HIF1A Q16665 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
FOXM1 Q08050 1/20 0.46
DHFR P00374 1/20 0.46
KMT2A Q03164 2/20 0.45
HRH3 Q9Y5N1 2/20 0.45
MEN1 O00255 1/20 0.45
CYP2D6 P10635 1/20 0.45
MAOB P27338 4/20 0.45
RAB9A P51151 3/20 0.45
MAOA P21397 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19556828 0.96 DHFR (0.45) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL8601201 0.96 LMNA (0.47) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL31473767 0.91 CYP1A2 (0.51) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL6768580 0.90 SRD5A2 (0.56) KMT2AMEN1MAOBRAB9ASMN1; SMN2
SCHEMBL27252707 0.88 DHFR (0.54) DHFRHRH3CYP2D6MAOBMAOA
SCHEMBL18354376 0.87 APP (0.46) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL30457667 0.85 DHFR (0.45) DHFRKMT2AMEN1LTA4H
SCHEMBL25221323 0.85 KMT2A (0.57) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL19504842 0.84 FFAR1 (0.50) KMT2AHRH3MEN1RAB9ASMN1; SMN2
SCHEMBL5864252 0.83 MEN1 (0.55) LMNADHFRKMT2AMEN1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111620764-B Selective ether bond cleavage method of aryl alkyl ether 荆楚理工学院 2023-05-05 CN disclosed
US-11046889-B2 Polymerizable compound and optically anisotropic body DIC CORPORATION (JP) 2021-06-29 US disclosed
US-10968189-B2 Method for producing 2-hydrazinobenzothiazole derivative DIC CORPORATION (JP) 2021-04-06 US disclosed
CN-111620764-A Selective ether bond breaking method of aryl alkyl ether 荆楚理工学院 2020-09-04 CN disclosed
US-20200165215-A1 METHOD FOR PRODUCING 2-HYDRAZINOBENZOTHIAZOLE DERIVATIVE DIC CORPORATION (JP) 2020-05-28 US disclosed
US-10633353-B2 Polymerizable compound, composition, polymer, optically anisotropic body, liquid crystal display element, and organic EL display DIC CORPORATION (JP) 2020-04-28 US disclosed
US-20170260150-A1 POLYMERIZABLE COMPOUND, COMPOSITION, POLYMER, OPTICALLY ANISOTROPIC BODY, LIQUID CRYSTAL DISPLAY ELEMENT, AND ORGANIC EL DEVICE DIC CORPORATION (JP) 2017-09-14 US disclosed
US-20170260150-A1 POLYMERIZABLE COMPOUND, COMPOSITION, POLYMER, OPTICALLY ANISOTROPIC BODY, LIQUID CRYSTAL DISPLAY ELEMENT, AND ORGANIC EL DEVICE DIC CORPORATION (JP) 2017-09-14 US disclosed
US-5811593-A MADE BY REACTING HYDROQUINONE MONOETHER WITH ENOL ETHER IN PRESENCE OF ACID CATALYST, REACTING PRODUCT WITH HYDROGEN TRANSFER AGENT IN PRESENCE OF METAL CATALYST TO CLEAVE PROTECTING GROUP THE PROCTER & GAMBLE COMPANY (US) 1998-09-22 US disclosed
EP-0748306-A1 PROCESS FOR MAKING MONOACETALS OF HYDROQUINONE THE PROCTER & GAMBLE COMPANY (US) 1996-12-18 EP disclosed
US-5585525-A Process for making monoacetals of hydroquinone THE PROCTER & GAMBLE COMPANY (US) 1996-12-17 US disclosed
WO-1995023779-A2 PROCESS FOR MAKING MONOACETALS OF HYDROQUINONE THE PROCTER & GAMBLE COMPANY (US) 1995-09-08 WO disclosed
WO-1995023778-A2 PROCESS FOR MAKING MONOACETALS OF HYDROQUINONE THE PROCTER & GAMBLE COMPANY (US) 1995-09-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170260150-A1 POLYMERIZABLE COMPOUND, COMPOSITION, POLYMER, OPTICALLY ANISOTROPIC BODY, LIQUID CRYSTAL DISPLAY ELEMENT, AND ORGANIC EL DEVICE RPL19, RPL24, RPL29 LMNA 2505/4885CYP1A2 4207/4885PTGS1 4068/4885
US-10633353-B2 Polymerizable compound, composition, polymer, optically anisotropic body, liquid crystal display element, and organic EL display RPL19, RPL24, RPL29 LMNA 2772/4885CYP1A2 4163/4885PTGS1 4244/4885
US-20200165215-A1 METHOD FOR PRODUCING 2-HYDRAZINOBENZOTHIAZOLE DERIVATIVE HAO2, IDH2, HACL2 LMNA 2566/4885CYP1A2 21/4885PTGS1 734/4885
US-11046889-B2 Polymerizable compound and optically anisotropic body OCIAD1, RCC1, OCIAD2 LMNA 1251/4885CYP1A2 917/4885PTGS1 1196/4885
US-10968189-B2 Method for producing 2-hydrazinobenzothiazole derivative HAO2, IDH2, HACL2 LMNA 2566/4885CYP1A2 21/4885PTGS1 734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.